Free Trial

Royalty Pharma (RPRX) Competitors

Royalty Pharma logo
$36.24 +0.51 (+1.43%)
Closing price 09/19/2025 04:00 PM Eastern
Extended Trading
$36.24 +0.00 (+0.01%)
As of 09/19/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RPRX vs. ZTS, JAZZ, CORT, PRGO, SUPN, PCRX, NKTR, OMER, ASMB, and CPIX

Should you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include Zoetis (ZTS), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceuticals" industry.

Royalty Pharma vs. Its Competitors

Royalty Pharma (NASDAQ:RPRX) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Royalty Pharma has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Zoetis had 28 more articles in the media than Royalty Pharma. MarketBeat recorded 41 mentions for Zoetis and 13 mentions for Royalty Pharma. Zoetis' average media sentiment score of 1.61 beat Royalty Pharma's score of 0.90 indicating that Zoetis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Royalty Pharma
7 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Zoetis
40 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Royalty Pharma currently has a consensus price target of $48.00, indicating a potential upside of 32.45%. Zoetis has a consensus price target of $200.88, indicating a potential upside of 37.75%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Royalty Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Royalty Pharma
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
Zoetis
0 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.56

Royalty Pharma has a net margin of 44.23% compared to Zoetis' net margin of 27.83%. Zoetis' return on equity of 56.90% beat Royalty Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Royalty Pharma44.23% 25.54% 14.11%
Zoetis 27.83%56.90%19.54%

Royalty Pharma pays an annual dividend of $0.88 per share and has a dividend yield of 2.4%. Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.4%. Royalty Pharma pays out 50.9% of its earnings in the form of a dividend. Zoetis pays out 34.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years and Zoetis has increased its dividend for 14 consecutive years.

Zoetis has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty Pharma$2.26B9.33$858.98M$1.7320.95
Zoetis$9.26B6.98$2.49B$5.8125.10

Summary

Zoetis beats Royalty Pharma on 14 of the 20 factors compared between the two stocks.

Get Royalty Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RPRX vs. The Competition

MetricRoyalty PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$21.13B$3.14B$5.77B$10.45B
Dividend Yield2.43%2.35%5.61%4.56%
P/E Ratio20.9520.9180.5026.82
Price / Sales9.33262.05455.1691.38
Price / Cash8.6446.4637.6661.43
Price / Book2.069.6015.756.39
Net Income$858.98M-$53.22M$3.30B$271.80M
7 Day Performance-0.33%3.11%5.35%3.51%
1 Month Performance-0.19%6.23%7.28%9.58%
1 Year Performance31.59%11.02%80.79%28.53%

Royalty Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RPRX
Royalty Pharma
4.8853 of 5 stars
$36.24
+1.4%
$48.00
+32.5%
+31.6%$21.13B$2.26B20.9580High Trading Volume
ZTS
Zoetis
4.8603 of 5 stars
$151.88
-0.9%
$202.43
+33.3%
-24.3%$67.31B$9.26B26.1413,800Positive News
JAZZ
Jazz Pharmaceuticals
4.4632 of 5 stars
$129.85
+0.3%
$178.67
+37.6%
+15.8%$7.86B$4.09B-19.292,800Positive News
CORT
Corcept Therapeutics
4.7786 of 5 stars
$71.23
+2.7%
$134.50
+88.8%
+90.6%$7.51B$675.04M63.04300Positive News
PRGO
Perrigo
4.7992 of 5 stars
$22.31
-1.5%
$33.00
+47.9%
-21.8%$3.07B$4.37B-38.468,379Analyst Downgrade
SUPN
Supernus Pharmaceuticals
2.8915 of 5 stars
$45.82
-0.4%
$43.00
-6.2%
+44.7%$2.57B$661.82M39.84580Analyst Upgrade
PCRX
Pacira BioSciences
3.2799 of 5 stars
$26.74
+1.1%
$30.83
+15.3%
+83.5%$1.20B$700.97M-9.62720Positive News
NKTR
Nektar Therapeutics
4.1444 of 5 stars
$44.33
+10.3%
$88.33
+99.3%
+182.8%$843.11M$74.93M-5.04220Trending News
Analyst Forecast
High Trading Volume
OMER
Omeros
3.794 of 5 stars
$4.21
+1.0%
$18.00
+327.6%
+6.6%$286.53MN/A-2.00210Analyst Upgrade
ASMB
Assembly Biosciences
3.448 of 5 stars
$23.32
-2.1%
$41.33
+77.2%
+25.9%$178.86M$28.52M-4.18100Positive News
High Trading Volume
CPIX
Cumberland Pharmaceuticals
0.2991 of 5 stars
$3.31
flat
N/A+158.2%$49.52M$37.87M-15.0580Positive News

Related Companies and Tools


This page (NASDAQ:RPRX) was last updated on 9/21/2025 by MarketBeat.com Staff
From Our Partners